Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-BED003
- Development stage
- Unknown
- Lead developer
- Blue Earth Diagnostics
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-BED003 is a Gallium-68 labeled PET radiopharmaceutical developed by Blue Earth Diagnostics (following its acquisition of Coxeter) for the imaging of various solid tumors. The agent is designed to target Fibroblast Activation Protein (FAP), a type II transmembrane serine protease that is significantly upregulated on cancer-associated fibroblasts (CAFs) within the tumor microenvironment of many epithelial cancers. Because FAP expression is minimal in healthy adult tissues but high in the stroma of over 90% of carcinomas, 68Ga-BED003 serves as a high-contrast diagnostic tool for Positron Emission Tomography (PET) imaging. It is intended to assist in tumor staging, identification of metastatic lesions, and potentially the selection of patients for FAP-targeted radioligand therapies. The drug is currently in Phase 1 clinical development.
- Other names
- [68Ga]Ga-BED00368Ga-BED003 FAP
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 68Ga-BED003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-BED003.